These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
424 related articles for article (PubMed ID: 15958540)
1. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Schepelmann S; Hallenbeck P; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Hay C; Hawkins LK; Marais R; Springer CJ Cancer Res; 2005 Jun; 65(12):5003-8. PubMed ID: 15958540 [TBL] [Abstract][Full Text] [Related]
2. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Schepelmann S; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Chen P; Marais R; Springer CJ Cancer Res; 2007 May; 67(10):4949-55. PubMed ID: 17510425 [TBL] [Abstract][Full Text] [Related]
3. Attenuated Salmonella targets prodrug activating enzyme carboxypeptidase G2 to mouse melanoma and human breast and colon carcinomas for effective suicide gene therapy. Friedlos F; Lehouritis P; Ogilvie L; Hedley D; Davies L; Bermudes D; King I; Martin J; Marais R; Springer CJ Clin Cancer Res; 2008 Jul; 14(13):4259-66. PubMed ID: 18594008 [TBL] [Abstract][Full Text] [Related]
4. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Friedlos F; Davies L; Scanlon I; Ogilvie LM; Martin J; Stribbling SM; Spooner RA; Niculescu-Duvaz I; Marais R; Springer CJ Cancer Res; 2002 Mar; 62(6):1724-9. PubMed ID: 11912146 [TBL] [Abstract][Full Text] [Related]
5. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus. Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667 [TBL] [Abstract][Full Text] [Related]
6. Self-immolative nitrogen mustard prodrugs for suicide gene therapy. Niculescu-Duvaz D; Niculescu-Duvaz I; Friedlos F; Martin J; Spooner R; Davies L; Marais R; Springer CJ J Med Chem; 1998 Dec; 41(26):5297-309. PubMed ID: 9857097 [TBL] [Abstract][Full Text] [Related]
7. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637 [TBL] [Abstract][Full Text] [Related]
8. Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. Davies LC; Friedlos F; Hedley D; Martin J; Ogilvie LM; Scanlon IJ; Springer CJ J Med Chem; 2005 Aug; 48(16):5321-8. PubMed ID: 16078849 [TBL] [Abstract][Full Text] [Related]
9. In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug. Spooner RA; Martin J; Friedlos F; Marais R; Springer CJ Cancer Gene Ther; 2000 Oct; 7(10):1348-56. PubMed ID: 11059693 [TBL] [Abstract][Full Text] [Related]
10. Significant differences in biological parameters between prodrugs cleavable by carboxypeptidase G2 that generate 3,5-difluoro-phenol and -aniline nitrogen mustards in gene-directed enzyme prodrug therapy systems. Niculescu-Duvaz I; Scanlon I; Niculescu-Duvaz D; Friedlos F; Martin J; Marais R; Springer CJ J Med Chem; 2004 May; 47(10):2651-8. PubMed ID: 15115406 [TBL] [Abstract][Full Text] [Related]
11. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895 [TBL] [Abstract][Full Text] [Related]
12. Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma. Roh V; Laemmle A; Von Holzen U; Stroka D; Dufour JF; Hunt KK; Candinas D; Vorburger SA Cancer Gene Ther; 2008 Oct; 15(10):636-44. PubMed ID: 18535617 [TBL] [Abstract][Full Text] [Related]
13. Increased efficacy and safety in the treatment of experimental liver cancer with a novel adenovirus-alphavirus hybrid vector. Guan M; Rodriguez-Madoz JR; Alzuguren P; Gomar C; Kramer MG; Kochanek S; Prieto J; Smerdou C; Qian C Cancer Res; 2006 Feb; 66(3):1620-9. PubMed ID: 16452221 [TBL] [Abstract][Full Text] [Related]
14. Tumor-targeted gene therapy using Adv-AFP-HRPC/IAA prodrug system suppresses growth of hepatoma xenografted in mice. Dai M; Liu J; Chen DE; Rao Y; Tang ZJ; Ho WZ; Dong CY Cancer Gene Ther; 2012 Feb; 19(2):77-83. PubMed ID: 21959967 [TBL] [Abstract][Full Text] [Related]
15. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Marais R; Spooner RA; Stribbling SM; Light Y; Martin J; Springer CJ Nat Biotechnol; 1997 Dec; 15(13):1373-7. PubMed ID: 9415889 [TBL] [Abstract][Full Text] [Related]